At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The move strengthens GBL’s clinical-stage presence in the United States
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Subscribe To Our Newsletter & Stay Updated
